【日本小林制药保健品原料曝出安全疑云：含“未预料到的物质”】据中国新闻网4月20日综合报道，日本知名制药企业小林制药近期遭遇产品质量风波。日本国立医药品食品卫生研究所的最新检测结果显示，该公司销售的一款含有红曲成分的保健品原料中，除已知的“软毛青霉酸”外，还发现了两种未在产品说明中列出的“未预料到的物质”。
这一发现引发了公众对小林制药保健品安全性的关注。据日媒4月19日报道，这两种不明物质的存在可能对消费者的健康构成潜在风险，但具体影响尚待进一步科学研究确定。小林制药公司已对此事展开紧急调查，并表示将尽快查明这些物质的性质和来源，以确保消费者权益不受损害。
小林制药作为日本知名的制药企业，其产品质量一直备受信赖。此次事件无疑对其品牌形象造成了一定冲击。公司发言人表示，小林制药将秉持公开透明的原则，及时向公众通报调查进展，并承诺如果发现任何问题，将立即采取召回措施。
目前，日本相关部门正对小林制药的保健品进行全面审查，以评估其安全性。同时，消费者被建议在官方调查结果出炉前，谨慎使用涉事产品。此事再次凸显了保健品监管的重要性，也提醒消费者在选择保健品时应保持警惕，关注产品安全信息。
英语如下：
News Title: “Japanese Media Reports Unidentified Substance in Kōbunsha Pharmaceutical Health Supplements, Sparking Safety Concerns”
Keywords: Kōbunsha Pharmaceutical, problematic health supplements, unforeseen substances
News Content: **Controversy Surrounds Kōbunsha Pharmaceutical’s Health Supplements: Unforeseen Ingredients Found** According to China News Service’s April 20th comprehensive report, the renowned Japanese pharmaceutical company Kōbunsha Pharmaceutical has recently faced a产品质量危机. The latest tests conducted by Japan’s National Institute of Health Sciences revealed that an herbal supplement ingredient, which contains red yeast rice, had not only the known “Monascus purpureus acid” but also two unforeseen substances that were not listed in the product information.
This discovery has raised public concerns over the safety of Kōbunsha Pharmaceutical’s health supplements. As per Japanese media reports on April 19, the presence of these unidentified substances might pose potential health risks to consumers, although the exact implications are yet to be determined through further scientific research. The company has launched an urgent investigation and vowed to swiftly identify the nature and origin of these substances to safeguard consumer rights.
Kōbunsha Pharmaceutical, a well-established pharmaceutical firm in Japan, has traditionally enjoyed a strong reputation for product quality. This incident has undoubtedly impacted its brand image. A company spokesperson assured that Kōbunsha Pharmaceutical will adhere to principles of transparency, promptly updating the public on the investigation progress. The company pledged to initiate a recall if any issues are discovered.
Currently, Japanese authorities are conducting a comprehensive review of Kōbunsha Pharmaceutical’s health supplements to assess their safety. In the meantime, consumers are advised to use the affected products with caution until the official investigation results are released. This incident underscores the importance of health supplement regulation and serves as a reminder for consumers to remain vigilant and informed about product safety when choosing supplements.
【来源】http://www.chinanews.com/gj/2024/04-20/10202416.shtml
Views: 1